Continuous positive airway pressure with or without liraglutide in obstructive sleep apnoea and type 2 diabetes (ROMANCE)
doi: 10.1016/j.cmet.2013.03.002 149 KlugeMAFettermanJLVitaJA
Tirzepatide, a dual GIP/GLP-1 receptor agonist, represents the newest class of weight loss medications with remarkable clinical trial results from the SURMOUNT studies (Jastreboff et al., NEJM, 2022)
In a meta-analysis study of 48,674 patients, researchers found that the average risk of post-endoscopy aspiration pneumonia was 1.9% with various risk factors identified, including old age 65 years, coexisting pulmonary disease, coexisting cerebrovascular disease, remnant stomach, sedation with propofol, and long procedural duration
Levy will consider your current health status, medical history, and any other medications you might be taking before making a decision